Neoadjuvant Folfirinox Followed by Capecitabine and Limited Field Radiation for Localized Pancreatic Head Adenocarcinoma

• ClinicalTrials.gov Identifier: NCT01677988
• Recruitment Status: Terminated
• First Posted: September 3, 2012
• Results First Posted: January 15, 2016
• Last Update Posted: January 15, 2016
• Sponsor: Medical University of South Carolina
• Information provided by (Responsible Party): Paul O'Brien, Medical University of South Carolina

Study Description

Brief Summary:

This study is for subjects with adenocarcinoma of the pancreas. The purpose of this research study is to determine the safety and effectiveness of modified Folfirinox and radiation therapy as treatment for adenocarcinoma (cancer) of the pancreas before surgery. Screening tests will be done to determine if subjects are eligible for participation in this study. If subjects are eligible to participate and agree to participate they will begin chemotherapy. After 3 cycles of chemotherapy, subjects will begin chemoradiation. Within 4 to 8 weeks of completing radiation therapy, subjects will have surgery. There will also be post-treatment and follow-up evaluations. Subjects will be followed for every 3 months for 3 years after their initial registration.

Condition or disease	Intervention/treatment	Phase
Adenocarcinoma of Head of Pancreas	Drug: Neo-adjuvant Chemotherapy; Radiation: Chemoradiation; Procedure: Surgical Resection	Phase 2

Study Design

• Study Type: Interventional (Clinical Trial)
• Actual Enrollment: 3 participants
• Allocation: N/A
• Intervention Model: Single Group Assignment
• Masking: None (Open Label)
• Primary Purpose: Treatment
• Official Title: Phase II Study of Neoadjuvant Folfirinox Chemotherapy Followed by Capecitabine With Concurrent Limited Field Radiation Therapy in Patients With Localized Pancreatic Head Adenocarcinoma
• Study Start Date: July 2012
• Actual Primary Completion Date: October 2015

Arms and Interventions

Arm

Intervention/treatment

Experimental: Chemotherapy, Chemoradiation, Surgery; Neoadjuvant Chemotherapy- Modified FOLFIRINOX chemotherapy Day 1 and Day 15 of 28 day cycles for 3 cycles with growth factor support Chemoradiation Surgical Resection

Drug: Neo-adjuvant Chemotherapy; Modified FOLFIRINOX chemotherapy Day 1 and Day 15 of 28 day cycles, for three (3) cycles with growth factor support.; Restaging # 1. (CT or MRI; use same modality as baseline staging unless otherwise indicated by Study Team) Progressive Disease (PD) → Off study. Subsequent treatment per patient's primary MD. Stable Disease (SD) or Tumor Response → Continue to Registration #2 for Chemoradiation.; Other Name: FOLFIRINOX chemotherapy; Radiation: Chemoradiation; Chemoradiation may be administered at selected approved CTN sites.; Determination of resectability as reviewed and documented by MUSC-HCC GI Tumor Board. Unresectable → Off study. Subsequent treatment per patient's primary MD. Resectable → Continue to Registration #3 for Surgical Resection; Procedure: Surgical Resection; Meets criteria for resectable* →pancreaticoduodenectomy (POD); At time of resection, snap frozen tumor specimen sent for correlative biomarker studies

Outcome Measures

Primary Outcome Measures :

1. Estimate the R0/R1 Resection Rate [ Time Frame: at time of surgery ]
   Estimate the R0/R1 resection rate as the proportion of patients with R0 or R1 resection status based on the ITT population. R0 resection status is macroscopic complete removal of tumor by non-contaminated operation, with neither macroscopic nor microscopic residual tumor. R1 resection status is macroscopic complete removal of tumor by non-contaminated operation, with microscopic residual tumor.

Secondary Outcome Measures :

1. Radiographic Tumor Response [ Time Frame: From enrollment to Surgery ]
   The rate of CR, PR, SD and PD will be estimated as described in Section 14B prior to chemoradiation start and prior to surgery. The analysis population for estimation of radiographic response rate will be the ITT population.
2. Histopathologic Tumor Response [ Time Frame: at the time of surgery ]
   Estimate the rate of good histopathologic response as the proportion of grade I and II responders. The analysis population for this objective is the ITT population. Any patient for whom a surgical sample is not available will be considered a poor-responder.
3. Time to Recurrence: [ Time Frame: 2 years ]
   Time to recurrence is defined as the time from surgical resection to disease recurrence or death from any cause. Patients who have not recurred at the end of follow up will have their recurrence time censored at the last date of contact.
4. Overall Survival: [ Time Frame: 2 years ]
   Overall survival is defined as the time from enrollment to death from any cause. Patients still alive at the end of follow up will have their survival time censored at the last date of contact.

Other Outcome Measures:

1. Feasibility Objective [ Time Frame: From enrollment to end of chemotherapy part of the study ]
   The feasibility of treating patients with localized pancreatic head adenocarcinoma with this neoadjuvant regimen will be evaluated by estimating the proportion of patients completing five of six planned doses. The analysis population will be the ITT population.
2. CTC Analysis [ Time Frame: End of study ]
   To evaluate and describe CTC numbers, CTC phenotype characteristics and effectiveness/rate of CTC culturing techniques from patients with pancreatic adenocarcinoma.
3. CTC Expression [ Time Frame: 2 years ]
   To determine and evaluate the correlation between expression or biomarkers in the CTCs and expression of biomarkers in resected tissue specimens within the same cancer patient.

Eligibility Criteria

• Ages Eligible for Study: 18 Years to 80 Years (Adult, Older Adult)
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: No

Criteria

Inclusion Criteria:

• Patient has histologically or cytologically confirmed borderline resectable adenocarcinoma of the pancreas. Patients with islet cell or other neuroendocrine neoplasms are excluded.
• Borderline resectable disease as outlined in the protocol
• ≥ 18 years of age.
• Male or non-pregnant and non-lactating female. If a female patient is of childbearing potential, she must have a negative serum pregnancy test (β hCG) documented within 72 hours of the first administration of study drug.
• If sexually active, the patient must agree to use contraception considered adequate and appropriate by the Investigator.
• Patient must not have received prior chemotherapy or radiation for pancreatic cancer and no exposure to systemic chemotherapy.
• Patient have acceptable blood counts, chemistries & coagulation at baseline as outlined in the protocol
• Patient has an ECOG performance status PS 0-1.
• Patient has been informed about the nature of the study and has agreed to participate in the study and signed the Informed Consent Form prior to participation in any study-related activities.
• Endoscopic ultrasound (EUS) with FNA for cytology.
• Patients should not have any evidence of active or uncontrolled infection requiring treatment with antibiotics.

Exclusion Criteria:

• Patient has localized resectable, locally advanced unresectable or advanced metastatic disease. Patients with adenocarcinoma of the pancreatic body or tail are ineligible.
• Patient has active, uncontrolled bacterial, viral, or fungal infection(s) requiring systemic therapy.
• Patient has known infection with HIV.
• Patient has undergone major surgery, other than diagnostic surgery (i.e.surgery done to obtain a biopsy for diagnosis without removal of an organ), within 4 weeks prior to Day 1 of treatment in this study.
• Prior chemotherapy, immunotherapy or radiation for pancreatic cancer.
• Patient has a history of allergy or hypersensitivity to the study drugs.
• Patient has serious medical risk factors involving any of the major organ systems such that the Investigator considers it unsafe for the patient to receive chemotherapy and/or radiation therapy.
• Patients must not require chronic use of immunosuppressive agents (e.g. methotrexate, cyclosporine).
• No other prior malignancy is allowed except for the following: adequately treated basal cell or squamous cell skin cancer, in situ cervical cancer, adequately treated Stage I or II cancer from which the patient is currently in complete remission, or any other cancer from which the patient has been disease-free for five years.
• Patients must not have clinically significant cardiovascular disease (including myocardial infarction, unstable angina, symptomatic congestive heart failure, serious uncontrolled cardiac arrhythmia) < 1 year before randomization.
• Patients must not have a history of any medical or psychiatric condition or laboratory abnormality that in the opinion of the investigator may increase the risks associated with the study participation or investigational product(s) administration or may interfere with the interpretation of the results.
• Patient is unwilling or unable to comply with study procedures.
• Patient is enrolled in any other therapeutic clinical protocol or investigational trial.
• Patients aged > 70

Contacts and Locations

Locations

United States, South Carolina

Medical University of South Carolina

Charleston, South Carolina, United States, 29425

Sponsors and Collaborators

Medical University of South Carolina

Investigators

• Principal Investigator: Paul E. O'Brien, MD; Medical University of South Carolina

More Information

• Responsible Party: Paul O'Brien, Assistant Professor, Medical University of South Carolina
• ClinicalTrials.gov Identifier: NCT01677988
• Other Study ID Numbers: 101822
• First Posted: September 3, 2012
• Results First Posted: January 15, 2016
• Last Update Posted: January 15, 2016
• Last Verified: July 2015

Keywords provided by Paul O'Brien, Medical University of South Carolina:

NEOADJUVANT FOLFIRINOX CHEMOTHERAPY; LOCALIZED PANCREATIC HEAD ADENOCARCINOMA; RADIATION THERAPY

Additional relevant MeSH terms:

Adenocarcinoma; Carcinoma; Neoplasms, Glandular and Epithelial; Neoplasms by Histologic Type; Neoplasms; Folfirinox; Antineoplastic Agents